title: Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase.
abstract: MDA-MB-435S human breast cancer cells (435S) secrete nucleoside diphosphate kinase (NDPK) that supports metastases and is inhibited by epigallocatechin gallate (EGCG) and ellagic acid (EA). We hypothesise that 435S cell-secreted NDPK-B supports tumour formation by modulating ATP levels locally to activate endothelial cell (EC) P2Y receptor-mediated angiogenesis. Epigallocatechin gallate (IC50=8-10 microM) and EA (IC50=2-3 microM) suppressed 435S cell growth, but had less effect on human CD31+ EC growth. Epigallocatechin gallate (IC50=11 microM) and EA (IC50=1 microM) also prevented CD31+ EC tubulogenesis on Matrigeltrade mark. 435S cell-conditioned media induced tubulogenesis in a cell number, time, and nucleotide-dependent manner. Ellagic acid (1 microM), but not equimolar EGCG, reduced cell number-dependent angiogenesis. P2Y 1 receptor activation by NDPK-generated nucleotide (100 microM ATP) or by 10 microM 2-methyl-thio-ATP (2MS-ATP) promoted tubulogenesis on collagen and was blocked by the P2Y 1 antagonist MRS2179 (10 microM). Physiological amounts of purified as well as 435S cell-secreted NDPK also promoted angiogenesis that was attenuated by NDPK depletion or 10 microM MRS2179, indicating a P2Y 1 receptor-mediated pathway. These results support the notion that secreted NDPK mediates angiogenesis via P2Y receptor signalling and suggests that novel inhibitors of NDPK may be useful as therapeutics.
authors.affiliation: Department of Pharmacology MS318, University of Nevada School of Medicine, 1664 N Virginia Street, Reno, NV 89557, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Rumjahn
authors.forename: M A
authors.initials: MA
authors.lastname: Javed
authors.forename: N
authors.initials: N
authors.lastname: Wong
authors.forename: W E
authors.initials: WE
authors.lastname: Law
authors.forename: I L O
authors.initials: IL
authors.lastname: Buxton
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology; D001943:Breast Neoplasms / Q000201:enzymology* / Q000378:metabolism; D002392:Catechin / Q000031:analogs & derivatives / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004610:Ellagic Acid / Q000494:pharmacology; D042783:Endothelial Cells / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D006801:Humans; D009389:Neovascularization, Pathologic / Q000139:chemically induced / Q000201:enzymology*; D009701:Nucleoside-Diphosphate Kinase / Q000378:metabolism*; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D004610:Ellagic Acid; D000255:Adenosine Triphosphate; D002392:Catechin; C045651:epigallocatechin gallate; D009701:Nucleoside-Diphosphate Kinase